Hospira is voluntarily recalling three lots of the injectable opioid medication Hydromorphone HCl because the glass vials may be broken or cracked, the Food and Drug Administration announced yesterday. Hospira has notified hospitals and others with an existing inventory of the lots subject to this recall that they should stop use and distribution of the remaining units and quarantine them immediately. See the FDA announcement for more information, including the lot numbers. Health care professionals are encouraged to report any related problems or events to the FDA's MedWatch Program. Last week, the AHA and others asked the Drug Enforcement Administration to temporarily adjust the aggregate production quotas for certain injectable opioid medications in short supply to allow other manufacturers to supply product until the shortages resolve.
 

Related News Articles

Headline
“Safety Speaks” is a new Advancing Health series where hospital and health system leaders share successes from their organizations’ patient safety efforts. In…
Headline
The AHA June 7 submitted comments on a discussion draft of the Drug Shortage Prevention and Mitigation Act, bipartisan legislation proposing to provide…
Blog
The inability of many patients to obtain needed drug therapies due to either high prices or shortages has negatively affected patient outcomes.1 Nearly 30% of…
Headline
A new issue brief from AHA’s Hospitals Against Violence initiative offers proven strategies and action steps to help hospitals and health systems’ violence…
Headline
AHA urged leaders of the Senate and House Appropriations Subcommittees on Labor, Health and Human Services, and Education to give favorable funding…
Headline
The Department of Justice May 9 announced the formation of a task force focusing on competition concerns in health care. The unit, the Task Force on Health…